Darae Strategic Commercialization Center Co., Ltd. (CEOs Bae Sun-gu and Kim Jeong-guk), a leading expert in technology-based listing consulting, and RudaCure Inc. (CEO Yongho Kim), a drug developer targeting sensory disorder diseases, have solidified their strategic partnership.
On the 4th, the two companies signed an 'MOU for IP Portfolio Strategy Development and Technology-Based Listing Evaluation Consulting for RudaCure Inc.'
Through this MOU and investment, Darae Strategic Commercialization Center will provide comprehensive consulting to RudaCure Inc.—which is planning a technology-based listing—including mock evaluations for technology-based listing, IP portfolio and R&D strategy, and investment support, in order to help RudaCure Inc. successfully achieve a stable technology-based listing with its excellent technologies and drugs.
Darae Strategic Commercialization Center holds the highest reputation in the pharmaceutical and bio consulting industry, consulting dozens of pharmaceutical and bio companies each year. It provides a wide range of consulting services including technology-based listing consulting, IP consulting, R&D strategy, and technology valuation, and is also actively involved as an accelerator and investor. Recently, the company has been concentrating its capabilities on technology-based listing consulting for pharmaceutical and bio companies.
RudaCure Inc. has already had licensing experience with dry eye disease treatments and corneal damage treatments in 2021 and 2023, and is currently developing a best-in-class powerful non-narcotic analgesic. The company is developing innovative drugs for various intractable diseases targeting GTPase and ion channels, and is actively conducting research on psoriasis, atopic dermatitis, and anticancer agents. As a bio-venture company pursuing continuous growth through joint research and co-development with domestic and international pharmaceutical companies, RudaCure is well-positioned for future expansion.
RudaCure Inc. CEO Yongho Kim said, "Through substantive mutual cooperation with Darae Strategic Commercialization Center, with whom we have built a relationship over the past three years, we will grow into a bio-venture company with even stronger intellectual property and differentiated technologies going forward," expressing expectations for the strategic collaboration.
RudaCure Inc. is currently identifying compounds effective for chemotherapy-induced and cancer-related pain, and is preparing to present the technology at the 2023 ASCO conference. As a member of the clinical trial delegation, the company plans to simultaneously engage in exchange and technology promotion regarding anticancer clinical trials on-site.
Yakup Sinmun: RudaCure "Formally begins preparations for technology-based IPO listing"